



**UNITED DRUG**  
**International Healthcare Services**

# Contents

---

- ❑ United Drug – International Healthcare Services
- ❑ 2009 Interim Review
  - Trading Highlights
  - Financial Review
- ❑ Business risks and opportunities
- ❑ Summary

# United Drug | International Healthcare Services

---

- ❑ International provider of services to healthcare manufacturers and pharmaceutical retailers
- ❑ Strong positions in wholesale and pre-wholesale business with strong cash generation – UK and Ireland
- ❑ Range of services to meet healthcare manufacturers growing outsourcing requirements:
  - Medical & Scientific
  - Contract Sales & Marketing
  - Contract Packaging
  - Speciality Distribution
  - Homecare

in Europe and US

- ❑ Annual turnover over €1.65 billion
- ❑ Over 4,500 employees

## TRADING HIGHLIGHTS

- ❑ Strengthened wholesale positions
- ❑ Reduced consumer and government spending impacting on consumer products and Medical & Scientific businesses
- ❑ Strong performance in Contract Sales & Marketing
- ❑ Delays in customer decision making impacting on packaging business
- ❑ Revised divisional structure to improve offering and drive efficiencies on track to deliver €7-8 million annualised savings
- ❑ Fall in value of sterling reduces reported revenues and profits

# 2009 H1 Financial Review

	2009	2008	% Inc / (Dec)	Constant Currency % Inc / (Dec)
	€mn	€mn		
Revenue	850.9	845.1	1	6
EBITDA*	41.9	41.8	-	7
EBIT**	35.0	36.6	(4)	5
PBT**	30.0	33.3	(10)	-
EPS** (cent)	10.63	12.13	(13)	(3)
Dividend per share	2.23	2.23	-	-

\*before exceptional item

\*\*before exceptional item and intangible amortisation

# 2009 H1 Financial Review

	2009 €mn	2008 €mn	% Inc / (Dec)	Constant Currency % Inc / (Dec)
<b>Revenue</b>				
HSC	717.5	756.4	(5.1)	(1.2)
CSMS	76.7	56.5	35.8	56.9
P&S	56.7	32.2	75.7	74.3
	<u>850.9</u>	<u>845.1</u>	<u>0.7</u>	<u>5.6</u>
<b>EBIT*</b>				
HSC	26.6	27.7	(4.0)	3.3
CSMS	6.9	5.2	31.1	51.6
P&S	2.4	4.3	(43.0)	(39.5)
	<u>35.9</u>	<u>37.2</u>	<u>(3.6)</u>	<u>5.2</u>
<b>Stock option expense</b>	(0.9)	(0.6)		
	<u>35.0</u>	<u>36.6</u>	<u>(4.3)</u>	<u>4.7</u>

HSC Healthcare Supply Chain  
 CSMS Contract Sales & Marketing Services  
 P&S Packaging & Speciality

\*before amortisation and exceptional item

# 2009 H1 Financial Review

## Balance Sheet

	31.3.09	30.9.08	31.3.08
	€mn	€mn	€mn
<b>Net Debt</b>	209.0	159.1	82.7
<b>Interest Cover (times)</b>			
EBITA	7.0	10.2	11.0
EBITDA	8.3	11.5	12.6
<b>Net Debt/EBITDA (times)</b>	2.24	1.65	0.99

Debt: €200mn bank facilities; \$100mn private placement.  
First maturity (\$40mn) mid 2011

# Business Risks And Opportunities

---

## Risks

- Government intervention on prices/margins or changes in spending
- M&A activity amongst outsourcing clients
- Contract cancellations or delays in outsourcing businesses
- FX movements

## Opportunities

- Strong position in defensive, cash generative, wholesale and pre-wholesale
- Increasing outsourcing trends amongst healthcare manufacturers.
- Restructuring driving efficiencies
- M&A opportunities in fragmented key strategic areas
- Balance sheet

# Summary

---

- ❑ Strong positions in defensive wholesale and pre-wholesale markets
- ❑ Positioned to benefit from increased outsourcing trend
- ❑ Continued diversification by geography and business sector
- ❑ Infrastructure and Balance Sheet to support growth objectives